Transforming growth factor-β-activated kinase 1 and pathological myocardial hypertrophy / 生理学报
Acta Physiologica Sinica
;
(6): 499-505, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-827037
ABSTRACT
The transforming growth factor-β-activated kinase 1 (TAK1) is a member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family. TAK1 plays important roles in many biological functions. Cardiac hypertrophy can be identified as physiological or pathological myocardial hypertrophy. TAK1 not only participates in the development of normal myocardium, but also plays an important role in regulating the occurrence and development of pathological myocardial hypertrophy. Angiotensin II (Ang II) or pressure overload induces pathological cardiac hypertrophy through different ways, such as hypoxia-inducible factor-1α (HIF-1α)-mediated transcriptional expression of TAK1, or transforming growth factor-β1 (TGF-β1)-, thyroid hormone-, ubiquitin protease-mediated TAK1 phosphorylation or ubiquitination. This article reviews the role of TAK1 in the occurrence and development of pathological myocardial hypertrophy and discusses the potential of TAK1 as an important target for the prevention and treatment of clinical myocardial hypertrophy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphorylation
/
Transforming Growth Factor beta
/
Cardiomegaly
/
MAP Kinase Kinase Kinases
/
Transforming Growth Factor beta1
/
Genetics
/
Myocardium
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Acta Physiologica Sinica
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS